The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

UPDATE ON FLEXION THERAPEUTICS $FLXN $SYN

March 23, 2017

This post was just published on ZYX Buy Change Alert. The stock has surged to over $26 as of this writing. Consider not chasing the price.  If you do not have a fill, we are raising the top end of the buy zone to $24.31 and the preferred point is being raised to $23.36. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

INTELLIGENCE: A NEW IDEA ON FLEXION THERAPEUTICS, RUMORS OF A BUYOUT $FLXN $SNY

March 23, 2017

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage. FLXN is a biopharma. There are reports of a potential buyout buy SNY.  The stock is jumping as we are writing.  This is suitable only for super aggressive investors as the risk of loss

Read More »

THE REAL REASON BEHIND THE GOLD MOVE IS NOT WHAT YOU THINK, EXTRACTING PROFITS TRADE AFTER TRADE $NUGT $GLD $SLV

March 22, 2017

The real reason behind gold move is not what you think.  It is the healthcare bill as I will explain later in this article.  I will also show you how at The Arora Report we are extracting profits trade after trade from precious metals with a real live example of a trade that is in progress as of this writing. In addition to taking very long term positions in precious metals, at The Arora Report we also selectively undertake short-term trades.  Short-term trades are not for everyone, but those who can handle them correctly, profits can be substantial. To fully

Read More »

SIGNAL: 79% – 150% RETURN ON APPLIED MATERIALS, NOW IN THE TARGET ZONE, TAKE PARTIAL PROFITS, RAISING THE TARGET, % DIP TO BUY IF NOT HOLDING $AMAT

March 21, 2017

This post was just published on ZYX Buy Change Alert. AMAT makes semiconductor manufacturing equipment.  This has been one of the strongest stocks in Trump rally.  AMAT is also in the Model Portfolio.  Depending upon when and how you bought AMAT, you are looking at 79% to 150% return in about a year or less.  Of course those who bought recently would have a lower return. Our target has been $38 to $41.  The stock jumped up to close at $39.60.  We are raising the target zone to $48 to $56. Recommended position size has been 30% to 50% of the full

Read More »

A NEW TRADE IDEA: BIOTECH COMPANY MAY HAVE A CURE FOR THE CANCER THAT KILLED APPLE’S STEVE JOBS $AAAP $AAPL $IBB $LABD $XBI $LABU

March 17, 2017

I’m constantly exposed to speculative biotechnology companies with promising treatments. But few pass our investing screens. Advanced Accelerator Applications SA AAAP,  a 15-year-old French radiopharmaceutical company, has been getting a lot of publicity. The company claims to be close to bringing to market a therapy that targets the cancer that killed Apple Inc. AAPL, founder Steve Jobs: an unusual form of pancreatic cancer known as a neuroendocrine tumor or islet cell carcinoma. The company, which has a market value of $1.6 billion, has other therapies in the pipeline and also a diagnostics business. Advanced Accelerator Applications’ latest quarterly report showed

Read More »

TAKE PARTIAL PROFITS ON MICRON TECHNOLOGY $MU

March 17, 2017

This post was just published on ZYX Buy Change Alert. MU is long from $21.77.  As of this writing it is trading at $25.83.  Those holding more than 25% may consider taking partial profits right here.  The reason is that Samsung is ramping up DRAM production. DRAMs are the primary source of revenue for MU.  DRAM is a commodity and prices can quickly get depressed. The reason for holding the remaining, is that Wall Street is in love with this stock and may push the stock higher.   Consider raising the protective stop on a 10% tranche in the zone of $24.23 to

Read More »

WEEKLY MARKET DIGEST: UPWARD PRESSURE FROM QUADRUPLE WITCH, RATE HIKES, MODI LANDSLIDE AND GOLD $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

March 17, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. QUADRUPLE WITCHING EXERTING UPWARD PRESSURE ON THE MARKET, WEAK INDUSTRIAL PRODUCTION, HIGHER OIL DEMAND, GOLD STEADY March 17, 2017 This is what you need to

Read More »

TYSON: ANOTHER REPORT OF BIRD FLU $TSN

March 16, 2017

This post was just published on ZYX Short Sell Change Alert. There is another report of bird flu in Tennessee.  TSN fell on the news but then rebounded in the afternoon on short covering.  There is a long-term short position in TSN.  TSN is a major vendor of chickens. The long-term target zone remains $38 to $45. The short zone remains $64 to $71. This stock can trade in a wide range.  The stock closed at $62.00. We have been telling you for a while that momentum of TSN earnings is not sustainable.  Wall Street fell in love with this stock after it

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content